LY2109761
A potent, selective and orally active TGF-β RI/II dual inhibitor with Ki of 38/300 nM, respectively; completely inhibits TGF-β-induced Sma2 phosphorylation on tumor cells or the liver microenviroment, inhibits the L3.6pl/GLT soft agar growth, suppresses both basal and TGF-β1-induced cell migration and invasion, and stimulates anoikis in vitro; significantly reduces the tumor burden as well as spontaneous abdominal metastases, and prolongs survival combined with gemicitabine in vivo model of pancreatic cancer.
Product Specifications
CAS Number
700874-71-1
Product Name Alternative
LY 2109761 | LY-2109761
Purity
>98% (HPLC)
Solubility
10 mM in DMSO
Smiles
N1 (CCOC2=CC=C3C (C4=C (CCC5) N5N=C4C6=NC=CC=C6) =CC=NC3=C2) CCOCC1
Molecular Formula
C26H27N5O2
Molecular Weight
441.5249
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Quinoline, 4-[5,6-dihydro-2- (2-pyridinyl) -4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2- (4-morpholinyl) ethoxy]-
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Cy3-Linked Polyclonal Antibody to Myelin Basic Protein (MBP)
Cy3-Linked Polyclonal Antibody to Myelin Basic Protein (MBP)
Cy3-Linked Polyclonal Antibody to Myelin Basic Protein (MBP)
Cy3-Linked Polyclonal Antibody to Myelin Basic Protein (MBP)
Cy3-Linked Polyclonal Antibody to Myelin Basic Protein (MBP)